The partners are also working together to validate the company's molecular testing technologies in various settings.
The firm revised its revenue guidance for full-year 2026 to a range of $802 million to $806 million, and its net loss for the year to a range of $42 million to $34 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results